Yong Kek Pang

Yong Kek Pang

Auto-generated profile, based on publicly available information

Yong Kek Pang

Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
CCChee-Shee Chai
Chee-Shee Chai
CLChong-Kin Liam
Chong-Kin Liam
YPYong-Kek Pang
Yong-Kek Pang
DNDiana Leh-Ching Ng
Diana Leh-Ching Ng
STSeng-Beng Tan
Seng-Beng Tan
JSJo-Ee Sia
Jo-Ee Sia
Introduction: The Spanish COPD guideline (GesEPOC) classifies COPD into four clinical phenotypes based on the exacerbation frequency and dominant clinical manifestations. In this study, we compared the disease-specific health-related quality of life (HRQoL) of patients with different clinical phenotypes. Methods: This was a cross-sectional study of patients with COPD attending the respiratory medicine clinic of University of Malaya Medical Centre from 1 June 2017 to 31 May 2018. Disease-specific HRQoL was assessed by using the COPD Assessment Test (CAT) and St George’s Respiratory Questionnaire for COPD (SGRQ-c). Results: Of 189 patients, 28.6% were of non-exacerbator phenotype (NON-AE), 18.5% were of exacerbator with emphysema phenotype (AE NON-CB), 39.7% were of exacerbator with chronic bronchitis phenotype (AE CB), and 13.2% had asthma-COPD overlap syndrome phenotype (ACOS). The total CAT and SGRQ-c scores were significantly different between the clinical phenotypes (P<0.001). Patients who were AE CB had significantly higher total CAT score than those with ACOS (P=0.033), AE NON-CB (P=0.001), and NON-AE (P<0.001). Concerning SGRQ-c, patients who were AE CB also had a significantly higher total score than those with AE NON-CB (P=0.001) and NON-AE (P<0.001). However, the total SGRQ-c score of AE CB patients was only marginally higher than those who had ACOS (P=0.187). There was a significant difference in the score of each CAT item (except CAT 7) and SGRQ-c components between clinical phenotypes, with AE CB patients recording the highest score in each of them. Conclusion: Patients who were AE CB had significantly poorer HRQoL than other clinical phenotypes and recorded the worst score in each of the CAT items and SGRQ-c components. Therefore, AE CB patients may warrant a different treatment approach that focuses on the exacerbation and chronic bronchitis components.

6 March 2026 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ZPZofia Piotrowska
Zofia Piotrowska
MAMyung-Ju Ahn
Myung-Ju Ahn
PVPei Jye Voon
Pei Jye Voon
YPYong-Kek Pang
Yong-Kek Pang
SHSoon Hin How
Soon Hin How
BCByoung Chul Cho
Byoung Chul Cho
ELIOS (NCT03239340) prospectively compared tumor biopsies obtained pre-treatment and post-progression to characterize acquired resistance mechanisms to first-line osimertinib in epidermal growth factor receptor (EGFR)-mutant advanced non–small cell lung cancer (NSCLC). Of 154 patients enrolled, 52 patients had next-generation sequencing (NGS) results from paired tissue biopsies. The most common acquired alterations at progression were MET amplification (17%), deletion of CDKN2A/CDKN2B (15%) and MTAP (13%), and EGFR C797S (13%). Proteogenomic analysis (n = 32 at baseline and n = 18 post-progression) showed TROP2 was highly expressed at baseline and post-progression, irrespective of genetic alterations observed. In a separate analysis of patients with matched tissue and plasma samples post-progression (n = 51), 82% had potential resistance alterations by NGS, demonstrating the complementary roles of tissue and plasma NGS. These results highlight the challenges of obtaining tissue biopsies in patients with NSCLC progressing on targeted therapy, the potential for heterogeneous resistance, and the need for broad-acting treatment strategies. Significance: ELIOS confirmed acquired resistance mechanisms to first-line osimertinib in a prospective, molecular profiling study of paired pre- and post-treatment tissue samples and provided the first proteogenomic characterization before/after osimertinib, identifying novel proteomic markers. ELIOS showed the potential for heterogeneous resistance, highlighting that strategies targeting multiple resistance pathways may be required.

7 July 2021 in npj Primary Care Respiratory Medicine
Verified
Journal Article
Open access
PDF file
PLPing Yein Lee
Ping Yein Lee
ACAi Theng Cheong
Ai Theng Cheong
SGSazlina Shariff Ghazali
Sazlina Shariff Ghazali
HSHani Salim
Hani Salim
JWJasmine Wong
Jasmine Wong
EKEe Ming Khoo
Ee Ming Khoo
Asthma self-management is a crucial component of asthma management. We sought to explore healthcare professionals’ (HCPs’) perceptions on barriers to asthma self-management implementation in primary care. We recruited 26 HCPs from six public primary care clinics in a semi-urban district of Malaysia in 2019. The analysis was done inductively. HCPs described barriers that resonated with the “COM-B” behaviour change framework. Capability-related issues stemmed from a need for specific self-management skills training. Opportunity-related barriers included the need to balance competing tasks and limited, poorly tailored resources. Motivation-related barriers included lack of awareness about self-management benefits, which was not prioritised in consultations with perceived lack of receptiveness from patients. These were compounded by contextual barriers of the healthcare organisation and multilingual society. The approach to implementation of asthma self-management needs to be comprehensive, addressing systemic, professional, and patient barriers and tailored to the local language, health literacy, and societal context.

27 October 2023 in Journal of Global Health
Verified
Journal Article
Open access
SCSoo Chin Chan
Soo Chin Chan
JEJulia Patrick Engksan
Julia Patrick Engksan
JNJayakayatri Jeevajothi Nathan
Jayakayatri Jeevajothi Nathan
JSJaspreet Kaur Sekhon
Jaspreet Kaur Sekhon
NHNorita Hussein
Norita Hussein
RCRESPIRE Collaboration
RESPIRE Collaboration
Chronic respiratory diseases (CRDs), which include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, interstitial lung disease (ILD), post-tuberculosis (post-TB), and lung cancer survivors, contribute to 7.4% of the global disease burden [1]. People with CRDs experience disabling symptoms such as breathlessness, reduced exercise intolerance, cough, and poor quality of life. Pulmonary rehabilitation (PR), a comprehensive […]

1 January 2020 in Journal of Medical Microbiology
Verified
Journal Article
Open access
HSHaida Subakir
Haida Subakir
YCYoong Min Chong
Yoong Min Chong
YCYoke Fun Chan
Yoke Fun Chan
MHM. Shahnaz Hasan
M. Shahnaz Hasan
MJMohamad Fadhil Hadi Jamaluddin
Mohamad Fadhil Hadi Jamaluddin
ISI-Ching Sam
I-Ching Sam
Introduction. Burkholderia pseudomallei (melioidosis) is an important cause of community-acquired pneumonia (CAP) in the tropics. Selective medium is recommended for laboratory diagnosis with non-sterile respiratory samples, while PCR is not routinely used due to variable reported performance. The effectiveness of these diagnostic modalities varies by site. Aim. To compare selective media and real-time PCR (qPCR) with routine media in detecting B. pseudomallei in CAP respiratory samples in a low-incidence setting in Kuala Lumpur, Malaysia. Methodology. Respiratory samples were routinely cultured on blood, chocolate and MacConkey agar (RESP-ROUTINE), and compared to culture on selective Ashdown medium (RESP-SELECTIVE) and qPCR. The gold standard was routine culture of B. pseudomallei from any site (ALL-ROUTINE). Results . B. pseudomallei was detected in 8/204 (3.9 %) samples. Overall sensitivity rates differed (P=0.03) for qPCR (100%), RESP-SELECTIVE (87.5%) and RESP-ROUTINE (50%). There was a trend towards lower median days to positive culture for RESP-SELECTIVE (1 day) compared to RESP-ROUTINE (2 days, P=0.08) and ALL-ROUTINE (2 days, P=0.06). Reagent costs for each additional detection were USD59 for RESP-SELECTIVE and USD354 for PCR. Conclusions. In a low-incidence setting, selective culture of respiratory samples on Ashdown was more sensitive and allowed quicker identification than routine media, at reasonable cost. Blood cultures are critical, confirming four cases missed by routine respiratory culture. Selective medium is useful in early pneumonia (pre-sepsis) and resource-limited settings where blood cultures are infrequently done. Real-time PCR is costly, but highly sensitive and useful for high-risk patients with diabetes, cancer or immunosuppressants, or requiring ventilation or intensive care.

1 January 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
CCChee-Shee Chai
Chee-Shee Chai
CLChong-Kin Liam
Chong-Kin Liam
MPMAU-ERN POH
MAU-ERN POH
DODiana Bee-Lan Ong
Diana Bee-Lan Ong
YPYong-Kek Pang
Yong-Kek Pang
AAAdlinda Alip
Adlinda Alip
Background: This study aims to determine the predictors of acquired exon 20 T790M mutation in advanced non-small cell lung cancer (NSCLC) patients harbouring sensitizing epidermal growth factor receptor (EGFR) mutation following the failure of first- or second- generation EGFR-tyrosine kinase inhibitor (TKI). Methods: This is a retrospective observational study of NSCLC patients with sensitising EGFR mutation experiencing disease progression (PD) whilst on first- or second-generation EGFR-TKIs with subsequent investigations to detect acquired T790M mutation at the University of Malaya Medical Centre from 1st January 2015 to 31st December 2017. Results: A total of 87 patients were included. Upon PD, acquired T790M mutation was found in 55 (63.2%) patients and was signi ficantly more common in patients who achieved partial response (PR) whilst on the EGFR- TKIs (p = 0.008) or had new lung metastasis upon PD (p = 0.048). It was less frequent in patients who developed new symptomatic brain lesions (p = 0.021). Patients with exon 19 deletion were more likely to acquire T790M mutation compared to those with exon 21 L858R point mutation (p = 0.077). Multivariate analysis revealed PR whilst on EGFR-TKI treatment was an independent predictor of acquiring T790M mutation (p = 0.021), whereas development of new symptomatic brain lesions (p = 0.034) or new lymph node metastases (p = 0.038) upon PD was independently against acquiring T790M mutation. Patients with exon 19 deletion were more likely to acquire T790M mutation compared to those with exon 21 L858R point mutation (odds ratio: 2.3, 95% con fidence interval: 0.84-6.25, p = 0.104). Conclusion: The best tumour response of PR to first- or second-generation EGFR-TKI treatment independently predicts acquired T790M mutation. Patients with exon 19 deletion are likely to acquire T790M mutation. This would prove useful for clinicians to prognosticate and plan subsequent treatments for patients with advanced NSCLC harbouring EGFR mutations.